Cargando…
Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification
BACKGROUND: Patient-derived xenograft (PDX) models are important tools in precision medicine and for the development of targeted therapies to treat cancer patients. This study aimed to evaluate our precision medicine strategy that integrates genomic profiling and preclinical drug-screening platforms...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557466/ https://www.ncbi.nlm.nih.gov/pubmed/28806950 http://dx.doi.org/10.1186/s12885-017-3525-9 |
_version_ | 1783257210530299904 |
---|---|
author | Oh, Doo-Yi Jung, Kyungsoo Song, Ji-Young Kim, Seokhwi Shin, Sang Kwon, Yong-Jun Oh, Ensel Park, Woong-Yang Song, Sang Yong Choi, Yoon-La |
author_facet | Oh, Doo-Yi Jung, Kyungsoo Song, Ji-Young Kim, Seokhwi Shin, Sang Kwon, Yong-Jun Oh, Ensel Park, Woong-Yang Song, Sang Yong Choi, Yoon-La |
author_sort | Oh, Doo-Yi |
collection | PubMed |
description | BACKGROUND: Patient-derived xenograft (PDX) models are important tools in precision medicine and for the development of targeted therapies to treat cancer patients. This study aimed to evaluate our precision medicine strategy that integrates genomic profiling and preclinical drug-screening platforms, in order to personalize cancer treatments using PDX models. METHODS: We performed array-comparative genomic hybridization, microarray, and targeted next-generation sequencing analyses, in order to determine the oncogenic driver mutations. PDX cells were obtained from PDXs and subsequently screened in vitro with 17 targeted agents. RESULTS: PDX tumors recapitulated the histopathologic and genetic features of the patient tumors. Among the samples from lung cancer patients that were molecularly-profiled, copy number analysis identified unique focal MET amplification in one sample, 033 T, without RTK/RAS/RAF oncogene mutations. Although HER2 amplification in 033 T was not detected in the cancer panel, the selection of HER2-amplified clones was found in PDXs and PDX cells. Additionally, MET and HER2 overexpression were found in patient tumors, PDXs, and PDX cells. Crizotinib or EGFR tyrosine kinase inhibitor treatments significantly inhibited cell growth and impaired tumor sphere formation in 033 T PDX cells. CONCLUSIONS: We established PDX cell models using surgical samples from lung cancer patients, and investigated their preclinical and clinical implications for personalized targeted therapy. Additionally, we suggest that MET and EGFR inhibitor-based therapy can be used to treat MET and HER2-overexpressing lung cancers, without receptor tyrosine kinase /RAS/RAF pathway alterations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3525-9) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5557466 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55574662017-08-16 Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification Oh, Doo-Yi Jung, Kyungsoo Song, Ji-Young Kim, Seokhwi Shin, Sang Kwon, Yong-Jun Oh, Ensel Park, Woong-Yang Song, Sang Yong Choi, Yoon-La BMC Cancer Research Article BACKGROUND: Patient-derived xenograft (PDX) models are important tools in precision medicine and for the development of targeted therapies to treat cancer patients. This study aimed to evaluate our precision medicine strategy that integrates genomic profiling and preclinical drug-screening platforms, in order to personalize cancer treatments using PDX models. METHODS: We performed array-comparative genomic hybridization, microarray, and targeted next-generation sequencing analyses, in order to determine the oncogenic driver mutations. PDX cells were obtained from PDXs and subsequently screened in vitro with 17 targeted agents. RESULTS: PDX tumors recapitulated the histopathologic and genetic features of the patient tumors. Among the samples from lung cancer patients that were molecularly-profiled, copy number analysis identified unique focal MET amplification in one sample, 033 T, without RTK/RAS/RAF oncogene mutations. Although HER2 amplification in 033 T was not detected in the cancer panel, the selection of HER2-amplified clones was found in PDXs and PDX cells. Additionally, MET and HER2 overexpression were found in patient tumors, PDXs, and PDX cells. Crizotinib or EGFR tyrosine kinase inhibitor treatments significantly inhibited cell growth and impaired tumor sphere formation in 033 T PDX cells. CONCLUSIONS: We established PDX cell models using surgical samples from lung cancer patients, and investigated their preclinical and clinical implications for personalized targeted therapy. Additionally, we suggest that MET and EGFR inhibitor-based therapy can be used to treat MET and HER2-overexpressing lung cancers, without receptor tyrosine kinase /RAS/RAF pathway alterations. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-017-3525-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-10 /pmc/articles/PMC5557466/ /pubmed/28806950 http://dx.doi.org/10.1186/s12885-017-3525-9 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Oh, Doo-Yi Jung, Kyungsoo Song, Ji-Young Kim, Seokhwi Shin, Sang Kwon, Yong-Jun Oh, Ensel Park, Woong-Yang Song, Sang Yong Choi, Yoon-La Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification |
title | Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification |
title_full | Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification |
title_fullStr | Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification |
title_full_unstemmed | Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification |
title_short | Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification |
title_sort | precision medicine approaches to lung adenocarcinoma with concomitant met and her2 amplification |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557466/ https://www.ncbi.nlm.nih.gov/pubmed/28806950 http://dx.doi.org/10.1186/s12885-017-3525-9 |
work_keys_str_mv | AT ohdooyi precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT jungkyungsoo precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT songjiyoung precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT kimseokhwi precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT shinsang precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT kwonyongjun precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT ohensel precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT parkwoongyang precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT songsangyong precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification AT choiyoonla precisionmedicineapproachestolungadenocarcinomawithconcomitantmetandher2amplification |